# US 2019/0375744 A1 · Thiazole derivative and applications thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375744 A1
- Document ID: US20190375744A1
- Status: Published application
- Kind: A1
- Application number: 16/476,797
- Filed: 2018-01-09
- Published: 2019-12-12
- Earliest claimed: 2017-01-09
- Assignees: Medshine Discovery Inc.
- Applicants: Medshine Discovery Inc.
- Inventors: Haiying He; Zhigan Jiang; Weihua Shi; Jianhua Xia; Jian Li; Shuhui Chen
- Web page: https://patentgrep.com/patent/US20190375744A1

## CPC

- C07D 417/12: linked by a chain containing hetero atoms as chain links
- A61P 31/22: for herpes viruses
- C07D 277/54: Nitrogen and either oxygen or sulfur atoms
- C07D 417/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed in the present invention are a new thiazole compound, particularly a compound represented by formula (I), a pharmaceutical composition thereof and applications thereof in the preparation of drugs for the treatment of diseases related to herpes simplex viruses.

## Claims

### Claim 1

A compound represented by formula (I), or an isomer or a pharmaceutically acceptable salt thereof,
wherein,
R1 is selected from H, C1-4 alkyl or C3-6 cycloalkyl;
R2 and R3 are independently selected from H, or are independently selected from C1-3 alkyl optionally substituted by 1, 2 or 3R;
R4, R5, and R6 are independently selected from H, F, Cl, Br or I, or are independently selected from the group consisting of phenyl, 5- to 6-membered heteroaryl, and 5- to 6-membered heteroaryl-O—, each of which is optionally substituted by 1, 2 or 3R;
ring A is selected from C5-7 cycloalkyl or 5- to 8-membered heterocycloalkyl;
R is selected from F, Cl, OH, NH2, —COOH, C1-3 alkyl, C1-3 alkoxy, —N,N-di(C1-3 alkyl)amino, or C1-3 alkyl-C(═O)O—;
the heteroatom or heteroatom group in the 5- to 6-membered heteroaryl and the 5- to 8-membered heterocycloalkyl is independently selected from —S—, —O—, —NH—, or N; and
in any of the above cases, the number of the heteroatom or heteroatom group is independently selected from 1, 2 or 3.

### Claim 2 (depends on 1)

The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 1, wherein R is selected from F, Cl, OH, NH2, —COOH, CH3,
or CH3—C(═O)O—.

### Claim 3 (depends on 1)

The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 1, wherein R1 is selected from H or

### Claim 4 (depends on 1)

The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 1, wherein R2 and R3 are independently selected from H, or are independently selected from the group consisting of CH3 and —CH2—CH3, each of which is optionally substituted by 1, 2 or 3R.

### Claim 5 (depends on 4)

The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 4, wherein R2 and R3 are independently selected from H, CH3, —CH2—OH, or —CH2—OAc.

### Claim 6 (depends on 5)

The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 5, wherein R2 is selected from H, CH3, —CH2—OH, or —CH2—OAc.

### Claim 7 (depends on 5)

The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 5, wherein R3 is selected from H or CH3.

### Claim 8 (depends on 1)

The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 1, wherein R4, R5 and R6 are independently selected from H, F, Cl, Br or I, or are independently selected from the group consisting of pyridyl, thiazolyl, and pyridyl-O—, each of which is optionally substituted by 1, 2 or 3R.

### Claim 9 (depends on 7)

The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 7, wherein R4, R5 and R6 are independently selected from H, F, Cl, Br or I, or are independently selected from the group consisting of
each of which is optionally substituted by 1, 2 or 3R.

### Claim 10 (depends on 9)

The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 9, wherein R4, R5, and R6 are independently selected from H, F, Cl,

### Claim 11 (depends on 10)

The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 10, wherein R4 is selected from H, F, Cl, or

### Claim 12 (depends on 10)

The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 10, wherein R5 is selected from H,

### Claim 13 (depends on 10)

The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 10, wherein R6 is selected from H, F, Cl, or

### Claim 14 (depends on 1)

The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 1, wherein ring A is selected from piperidyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyranyl, oxepanyl, cyclopentyl, or cyclohexyl.

### Claim 15 (depends on 1)

The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 1, wherein the moiety
is selected from:

### Claim 16 (depends on 15)

The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 15, wherein the moiety
is selected from:

### Claim 17 (depends on 16)

The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 16, wherein the moiety
is selected from:

### Claim 18 (depends on 1)

The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 1, which is selected from:
wherein
R1, R2, R3, R4, R5, and R6 are as defined in claim 1.

### Claim 19

A compound of a formula, or an isomer or a pharmaceutically acceptable salt thereof, wherein the formula is selected from the group consisting of

### Claim 20 (depends on 19)

The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 19, which is selected from:

### Claim 21 (depends on 1)

A pharmaceutical composition, comprising:
a therapeutically effective amount of the compound or the pharmaceutically acceptable salt thereof according to claim 1, and
a pharmaceutically acceptable carrier.

### Claim 22 (depends on 1)

A method for treating a disease associated with herpes simplex viruses, comprising administering to a subject in need thereof an effective amount of the compound, the isomer therefore or the pharmaceutically acceptable salt thereof according to claim 1.

### Claim 23 (depends on 21)

A method for treating a disease associated with herpes simplex viruses, comprising administering to a subject in need thereof an effective amount of the pharmaceutical composition according to claim 21.
